Testing two types of Coenzyme Q10 products
Comparative Single-dose Bioavailability Clinical Study of Two Different Coenzyme Q10 Products
This study tests which of two different Coenzyme Q10 products is better absorbed by healthy people aged 50 to 65 to help those with Coenzyme Q10 deficiency.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 35 (estimated) |
| Ages | 50 Years to 65 Years |
| Sex | All |
| Sponsor | University of Primorska Academic / other |
| Locations | 1 site (Izola) |
| Trial ID | NCT06736366 on ClinicalTrials.gov |
What this trial studies
This study is a randomized, open-label, two-period crossover trial that evaluates the bioavailability of two different coenzyme Q10 products in 35 healthy subjects aged 50 to 65. Participants will receive a single dose of each product, and the plasma concentration of coenzyme Q10 will be measured to assess absorption and effectiveness. The study aims to provide insights into which formulation may be more beneficial for individuals with coenzyme Q deficiency.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy individuals aged 50 to 65 who do not have any cardiovascular diseases, diabetes, or neurodegenerative disorders.
Not a fit: Patients with existing cardiovascular diseases, diabetes, neurodegenerative diseases, or those taking any food supplements may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify the more effective coenzyme Q10 product, potentially improving treatment options for patients with coenzyme Q deficiency.
How similar studies have performed: While studies on coenzyme Q10 have been conducted, this specific approach of comparing two products in a crossover design is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * subject informed consent form * aged between 50 and 65 years old * body mass for women 70± 5 kg and for men 85± 5 kg * non-smoking * healthy, without cardio-vascular diseases, diabetes, neurodegenerative diseases * absence of any prescribed medication during the study * willing to avoid a consumption of any food supplements at least 2 weeks before and during the study Exclusion Criteria: * cardio-vascular diseases, diabetes, neurodegenerative diseases, gastrointestinal disorders, pregnancy, breast-feeding * intake of any food supplements within two week of the beginning of the study * drug or alcohol abuse
Where this trial is running
Izola
- University of Primorska, Faculty of Health Sciences — Izola, Slovenia (Recruiting)
Study contacts
- Principal investigator: Ana Petelin, phD — University of Primorska, Faculty of Health Sciences
- Study coordinator: Zala Jenko Pražnikar, phD
- Email: zala.praznikar@upr.si
- Phone: 0038656626469
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.